Older patients are often underrepresented in clinical trials investigating the treatment of coronary drug-eluting stent (DES) restenosis, but outcome data is urgently needed in an ageing society. Thus, the aim of this observational, retrospective study was to close this lack of evidence.

Between January 2007 and February 2021, 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany. We compared the rates of cardiac death, myocardial infarction (MI) and repeat revascularization in 1105 patients (31.5 %) older than 75 years with 2406 patients (68.5 %) younger than 75 years. Survival was analyzed using the Kaplan-Meier method. Differences between the groups were tested with the log-rank test. Conventional multivariable analysis with adjustment for relevant variables was performed.

Older patients were more frequently female (30.1 % vs. 17.9 %, p < 0.001) and presented less frequently with stable angina (67.8 % vs. 72.0 %, p < 0.001). After 10 years, the rates of cardiac death were 56.8 % in older patients and 27.4 % in younger patients (HRadj, 2.45 [95 % CI, 2.09-2.88], p < 0.001). Accounting for the risk of death, no difference was found regarding the rates of MI while target lesion revascularization (TLR) occurred less frequently in older patients (24.2 % vs. 33.7 %; HRadj, 0.77 [95 % CI, 0.66-0.89], p < 0.001).

In the long-term, rates of cardiac death after percutaneous coronary intervention of DES-ISR were higher and TLR rates were lower in patients older than 75 years. There was no difference in the rates of MI.

Limited data are available for sex-related long-term outcomes of patients treated for coronary drug-eluting stent (DES) restenosis. The aim of this observational, retrospective analysis was to close this lack of evidence. Between January 2007 and February 2021, a total of 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany, of which 763 (21.7%) were female. Endpoints of interest were all-cause mortality and rates of repeat revascularization. Outcomes are presented as Kaplan-Meier event rates. Univariate and multivariate analyses were performed. Female patients were older (72.1 ± 10.4 versus 68.4 ± 10.4 years, p < 0.001) and suffered more often from diabetes (38.8% versus 34.4%, p = 0.029). There was no statistical difference regarding the clinical presentation and interventional treatment strategy. After 10 years, the risk of all-cause mortality was higher in female patients [hazard ratio (HR) 1.18 (1.02-1.35); p = 0.022]; however, after adjustment for age, the risk did not differ significantly between both sexes [adjusted HR 0.96 (0.83-1.11); p = 0.6]. Regarding target vessel revascularization (TVR) and non-target vessel revascularization (NTVR), the risk was lower in female patients [HR 0.73 (0.61-0.87); p < 0.001 and HR 0.74 (0.64-0.86); p < 0.001] even after age adjustment. No statistical differences were found regarding the risk of target lesion revascularization, target vessel myocardial infarction and stent thrombosis. In the long term, all-cause mortality after percutaneous coronary intervention of DES-ISR did not differ between both sexes after age adjustment. The risk of TVR and NTVR was lower in female patients even after age adjustment.

Meticulous implantation strategies (i.e. lesion predilatation, stent sizing and postdilatation) are known to decrease lesion-oriented adverse events (LOCE) following percutaneous coronary intervention (PCI) with bioresorbable scaffolds. Their impact on PCI with drug-eluting stents remains unclear.

To assess the impact of meticulous implantation strategies on long-term LOCE in PCI with everolimus-eluting stents (EES).

This substudy of the AIDA trial (NCT01858077) focused on the evaluation of predilatation, stent sizing and postdilatation through analyses of vessel and device diameters at various locations around the lesion. Their interrelations were assessed using quantitative coronary angiography across various lesion locations. Logistic regression was used to evaluate how predictors influenced the primary outcome LOCE, which includes target lesion revascularisation (TLR), target-vessel myocardial infarction (TV-MI) and definite stent thrombosis (ST).

LOCE occurred in 84 (7.7%) of 1098 lesions, mainly driven by TLR (63, 5.7%) and TV-MI (46, 4.2%), with ST occurring in 9 (0.8%) lesions. Predilatation and postdilatation were performed in 92 and 49% of lesions, respectively. The difference between the diameter of the predilatation balloon and the reference vessel diameter was significantly associated with an increased risk for LOCE (odds ratio 4.84, 95% confidence interval: 1.91-12.7) with significant interaction with diabetes (p for interaction = 0.04), thus disfavouring predilatation with oversized balloons.

The low LOCE rate (7.7%) over 5 years underscores the efficacy of PCI with EES. The use of 'oversized' balloons for predilatation was associated with an increased risk of LOCE by up to fivefold, a risk that was interestingly reduced in patients with diabetes mellitus.

Lipoprotein (a) [Lp(a)] is a biomarker of atherosclerotic cardiovascular disease, but its role in mental disorders is controversial. Our study aimed to explore the causality between Lp(a) levels and mental disorders by combining retrospective and Mendelian randomization (MR) studies.

All genome-wide association study datasets used in the MR study were obtained from UK Biobank, FinnGen, and the Psychiatric Genomics Consortium. The matched case-control study were based on electronic health records from the Second Affiliated Hospital of Nanchang University and NHANES III cohort.

In the MR analysis, Lp(a) had a positive causal effect on the longest period of depression [1.05 (1.02-1.08), P = 0.0001], the number of depressive episodes [1.03 (1.01-1.06), P = 0.009] and a weak negative effect on memory loss [0.84 (0.72-0.99), P = 0.039]. Meanwhile, bipolar and major depressive disorder status was causally associated with significantly lower Lp(a) levels [0.96 (0.93-0.98), P = 0.003]. Retrospective study revealed low Lp(a) levels were associated with a significantly higher risk of depression (n = 670) [1.273 (1.007, 1.609), P = 0.044], anxiety (n = 1284) [1.231 (1.041, 1.456), P = 0.015] and major depression (n = 538) [1.364 (1.012,1.841), P = 0.042].

This study found there is a causal relationship between the number and longest period of depressive episodes or memory loss and Lp(a), while bipolar disorder and major depressive disorder were associated with a significant causal effect on reduced Lp(a) levels. Future studies should focus on whether a sustained decrease in Lp(a) levels could cause the development of mental disorders, and which target value is suitable for clinical practice.

The effects of isolated heart rate (HR) and mean blood pressure (MBP) on myocardial injury after noncardiac surgery (MINS) have been investigated, but the combined impact of intraoperative HR and MBP remains unclear. This study aimed to assess the influence of the heart rate-mean arterial pressure ratio (HMR) on MINS to optimize hemodynamic management.

This retrospective cohort study included adult patients who underwent general anesthesia and postoperative troponin measurements at Meizhou People's Hospital. The primary exposure was the time-weighted area above the HMR threshold (1.0) (TWAAT-HMR > 1.0), and the primary outcome was MINS within one postoperative day. The diagnostic performance of TWAAT-HMR > 1.0, the time-weighted area under MBP < 60 mmHg, and the time-weighted area above HR > 100 bpm was evaluated using Receiver Operating Characteristic (ROC) analysis. Logistic regression and restricted cubic splines (RCS) were used to assess the association between HMR and MINS. Sensitivity analyses were conducted to confirm the robustness of the findings, and subgroup analyses examined potential interactions with age, sex, and body mass index.

Among 699 patients, the incidence of MINS was 9.4%. TWAAT-HMR > 1.0 demonstrated superior predictive accuracy for MINS compared to time-weighted areas under/above MBP and HR (AUC: 0.708 vs. 0.646 and 0.640, respectively). TWAAT-HMR > 1.0 was identified as an independent risk factor for MINS (odds ratio [OR] = 1.71, 95% confidence interval [CI] 1.35-2.17, p < 0.001). RCS analysis showed a linear increase in MINS risk with rising HMR (p for non-linearity = 0.507). Sensitivity and subgroup analyses supported the primary findings.

Elevated HMR is associated with a higher risk of MINS in adults undergoing general anesthesia. HMR monitoring may serve as a valuable parameter for optimizing perioperative hemodynamic management.

Early evaluation and treatment of patients with acute chest pain pose a massive challenge to the emergency care system worldwide. This study aims to determine the current burden and early management of acute chest pain presenting to the emergency departments (EDs) in China.

The Evaluation and Management of Patients with Acute ChesT pain study is a prospective, multicentre and provincially representative registry of acute chest pain patients in Chinese EDs.

A stratified random sampling design generated the province representative sample of 21 public hospitals with independent EDs in Shandong, China. Each participating site consecutively enrolled patients for at least 12 months from August 2015 to September 2017.

A total of 8349 adult patients presenting with acute chest pain or suspected acute coronary syndrome (ACS) were included.

The annual incidence of ED-assessed acute chest pain was estimated. The aetiology, process of care and 30-day major adverse cardiac events (MACE) of included patients were analysed.

The estimated annual incidence of ED-assessed acute chest pain was 96.6 (95% CI 95.9 to 97.3) per 100 000 adults, significantly increasing with age. The mean age of included patients was 63.8 years, with 57.9% males. Prehospital delay was a median of 2.8 (IQR, 1.2-10.3) hours, with 17.9% transported by ambulance. About 75.6% of patients received their first ECG within 10 min. Cardiac troponin was tested in 54.2%, with high-sensitivity cardiac troponin in 24.5% and serial troponins in 5.1% during the ED stay. Most (74.0%) were admitted to the inpatient ward, with a median ED stay of 65.0 (IQR, 27.0-385.0) min. Within 30 days, 6.8% experienced MACE. Among included patients, 62.9% were diagnosed with ACS, with specific management varying by ST-segment elevation status.

China's first regionally representative registry of acute chest pain revealed a lower incidence of ED-assessed cases but a higher proportion of high-risk patients compared with other countries. Gaps persist in aligning emergency management with guidelines. More programmes and policies are needed to enhance the quality of acute chest pain care in China.

This study was registered at URL: https://www.

gov (NCT02536677).

This prospective, two-centre study derived and validated predictive algorithms for the Siemens Atellica IM high-sensitivity cardiac troponin I (hs-cTnI) assay in the emergency department (ED).

Algorithms for predicting 30-day myocardial infarction (MI) Types 1 and 2 and death or non-ST-elevation MI (NSTEMI, Types 1 and 2) at index admission were developed from a derivation cohort of 1896 patients and validated using a synthetic data set with nearly 1 million patient cases. Performance was compared with the European Society of Cardiology algorithms for hs-cTnT (Roche Diagnostics) and hs-cTnI (Abbott Diagnostics). An admission hs-cTnI concentration < 5 ng/L had a negative predictive value (NPV) and sensitivity for 30-day MI or death of 99.5-99.7% and 98.1-98.8%, respectively, in the derivation cohort and validation data set. The NPV and sensitivity were ≥99.7% and ≥98.8% for ruling out index NSTEMI. A 0- to 1-h algorithm with baseline hs-cTnI concentration < 10 ng/L and Δ change < 3 ng/L had NPV of ≥99.5% and sensitivity ≥ 97.3% for predicting 30-day MI or death and a ≥99.5% sensitivity and NPV for index NSTEMI. Rule-in algorithms of either 0-h hs-cTnI ≥ 120 ng/L or 0- to 1-h Δ change ≥ 12 ng/L had positive predictive value ≥ 73% and specificity > 96% for 30-day MI or death and index NSTEMI. The results were comparable with established hs-cTn algorithms.

This study presents Siemens Atellica hs-cTnI algorithms for diagnosis and risk prediction in the ED with performance comparable with established hs-cTnT (Roche) and hs-cTnI (Abbott) algorithms.

Coronary calcification is a well-known marker of atherosclerotic plaque burden and a determinant of stent under expansion with unfavorable long-term outcomes.

This sub study of the randomized BIOVASC trial aimed to compare immediate complete revascularization (ICR) and staged complete revascularization (SCR) in patients with acute coronary syndrome (ACS) and multi vessel disease (MVD), stratified by calcification of the culprit lesion.

The primary endpoint consisted of a composite of all-cause mortality, myocardial infarction, unplanned ischemia driven revascularization (UIDR) and cerebrovascular events at 2 year follow-up. Secondary endpoints included the individual components of the primary composite and major bleedings. We used cox regression models to relate study endpoints with randomized treatment stratified by calcification of the culprit lesion.

The BIOVASC trial enrolled 103 patients with a moderately or severely calcified culprit lesion. The composite primary outcome occurred in 8/57 (14.3%) versus 9/46 (19.7%) patients randomized to ICR and SCR (hazard ratio [HR] 0.66% and 95% confidence interval [CI] 0.25-1.71, p = 0.39). In the non-calcified culprit lesions, there were 83 events in the ICR (12.4%) and 82 events in the SCR (11.9%) (HR 1.01 [0.75-1.37], p = 0.94, P-interaction = 0.42). There was no evidence of a differential effect of ICR vs. SCR on the primary endpoint in relation to culprit lesion calcification (P-interaction = 0.42).

No differential treatment effect of ICR versus SCR was observed when comparing the primary composite outcome between calcified and non-calcified culprit lesion.

Troponin is a crucial biomarker in the emergency department (ED). Current evidence does not support differentiation between an uncomplicated tachyarrhythmia and significant coronary artery disease (CAD). The aim of the present study was to assess the use of troponins to predict CAD and mortality in patients with acute atrial fibrillation/flutter (AF/AFL). This cohort study included 3,425 consecutive episodes with AF/AFL treated at the ED of the Medical University of Vienna between 2012 and 2024. Coronary angiography was performed in 251 cases. Patients were grouped according to the troponin levels (ng/L): 0-4; 5-14; 15-28; 29-51 and ≥ 52. Outcomes were significant CAD and mortality. Of all cases (n = 3,425), coronary angiography was performed within 30 days in 251 (7%); 115 (46%) had significant CAD. The rate increased with rising troponin levels: baseline troponin, ng/L, %: 5-14: 32, 15-28: 38, 29-51: 47, ≥ 52: 57; p = 0.028; serial troponin, ng/L, %: 5-14: 15, 15-28: 19; 29-51: 54; ≥ 52: 66; p < 0.001. Sensitivity for significant CAD at 5 ng/L was 99%; specificity at ≥ 52 ng/L was 77% and increased to > 92% at ≥ 92 ng/L. 713 patients (21%) died in an observation time of 13,771 years. A troponin value ≥ 15 ng/L was significantly associated with all-cause mortality. Prevalence of significant CAD increases with rising and dynamic troponin levels. Troponin thresholds for further diagnostics or interventions may be different in AF/AFL than in the general population. Elevated troponin levels at baseline and in subsequent measurements as well as significant changes are associated with an increased all-cause mortality.

Vascular access-site complications (VASC) can occur during chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

We compared the baseline and procedural characteristics, and outcomes of patients with versus without VASC in a large multicenter CTO PCI registry. VASC was defined as any of the following: small hematoma (hematoma < 5 cm), large hematoma (hematoma ≥ 5 cm), arteriovenous fistula, pseudoaneurysm and acute arterial closure.

VASC occurred in 158 of 16,810 CTO PCIs (0.9%). VASC patients were older (67 ± 11 vs. 64 ± 10 years, p < 0.001), more likely to be women (28.4% vs. 19.1%, p = 0.004) and less likely to be current smokers (18.9% vs. 27.2%, p = 0.026). They were more likely to have at least one femoral access (89.2% vs. 75.3%, p < 0.001) and less likely to have any radial access (38.0% vs. 52.3%, p < 0.001). Transfemoral access was more common in patients with VASC (60.1% vs. 45.7%, p < 0.001). VASC cases had higher J-CTO (2.57 vs. 2.38, p = 0.05) and PROGRESS-CTO major adverse cardiac events (MACE) scores (3.27 vs. 2.58, p < 0.001). They had similar technical (87.3% vs. 87.1%, p > 0.9) and procedural (82.3% vs. 85.9%, p = 0.2) success, but higher MACE (6.3% vs. 1.9%, p < 0.001) and bleeding (23.4% vs. 0.4%, p < 0.001). Female gender (odds ratio [OR] 1.95, 95% confidence intervals [CI] 1.24-3.00, p = 0.003), at least one femoral access (OR 2.02, 95% CI 1.09-4.04, p = 0.034) and sheath size (7-F: OR 2.16, 95% CI 1.12-4.60, p = 0.031; 8-F: OR 2.11, 95% CI 1.03-4.70,p = 0.051) were associated with VASC in multivariable analysis.

Female sex, femoral access and larger sheaths ≥ 7 F were associated with VASC in patients undergoing CTO PCI.

Major bleedings following coronary artery bypass grafting (CABG) have significant implications on outcomes in acute coronary syndrome (ACS) patients. Owing fears of fatal bleedings in case of urgent CABG, current guidelines recommend a cessation of P2Y12 receptor antagonists (P2Y12-RA) before cardiac surgery and opt against routine pre-treatment with a P2Y12-RA before coronary angiography (CA). However, sparse information exists outside randomized trials on the frequency of urgent CABG and the consequences of inappropriately long cessation of P2Y12-RA treatment in patients presenting with ACS.

In this observational single-center study, ACS patients presenting to an emergency department requiring a CABG were recruited consecutively during a 2-year enrolment period. Baseline characteristics, CABG-related bleedings and all-cause mortality were collected from electronical medical records and related to the timing of CABG and P2Y12-RA cessation.

A total of 1,502 ACS patients were included, herein 102 (6.8%) underwent urgent CABG. The majority (76.5%) received a routine P2Y12-RA pre-treatment predominantly ticagrelor in addition to low-dose aspirin before CA. 31 (30.4%) developed a CABG-related bleeding event. Bleeding probability was highest (HR: 4.77, 95%CI 2.20-10.37, p = 0.0001) when CABG was performed within 24 h after administration of dual anti-platelet therapy (DAPT). Despite high utilization rates of DAPT pre-treatment and high prevalence of CABG-related major bleedings, no fatal bleedings occurred.

Need of urgent CABG in ACS is infrequent and does not result in an excess of mortality. However, cessation of ticagrelor for at least 48 h before CABG is recommended to minimize rates of CABG-related bleedings.

To identify the association between preoperative inflammatory state and myocardial injury after noncardiac surgery (MINS) in older patients using systemic inflammation indicators neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) and to compare their clinical predictive values.

This study included patients aged ≥65 years who underwent noncardiac surgery between January 2017 and August 2019. The relationship between preoperative inflammatory state and MINS was investigated using univariate and multivariate logistic regression analyses. The predictive values of NLR, PLR, and SII were determined by receiver operating characteristic (ROC) curve analysis. Based on the basic model we constructed, the predictive values were compared through separately adding NLR, PLR and SII.

Among 12464 patients, 965 (7.74%) developed MINS. The optimal cut-off values of NLR, PLR, and SII were 597×109, 2.59, and 923. Univariate and multivariate analyses show that preoperative inflammatory state is associated with MINS. In the multivariate analysis, the OR values for NLR, PLR, and SII were (OR: 1.61, 95% CI: 1.36-1.89, p<0.001), (OR: 1.28, 95% CI: 1.07-1.52, p=0.006), and (OR: 1.43, 95% CI: 1.20-1.70, p<0.001). ROC curve analysis indicated that NLR was more predictive of MINS (area under the curve [AUC]: 0.671, 95% CI: 0.652-0.689) than PLR (AUC: 0.635, 95% CI: 0.616-0.655) and SII (AUC: 0.648, 95% CI: 0.628-0.667). The addition of the NLR to a basic prediction model improved its predictive ability to a greater extent than the addition of PLR and SII.

Higher preoperative inflammation levels are associated with an increased risk of MINS. The NLR, PLR, and SII are independent risk factors for MINS and NLR demonstrated better predictive value than that of PLR and SII.

Clinical characteristics and outcomes of patients with myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) are not fully understood, particularly in Japan.

We enrolled a total of 8881 patients with acute MI from the Miyagi Acute Myocardial Infarction Registry Study (2012-2020), with a median age of 69 years. Among them, 239 patients (2.7%) were diagnosed with MINOCA. Compared with those with MI with obstructive coronary artery disease (MI-CAD), patients with MINOCA were more often women, had a higher incidence of non-ST-segment-elevation MI and a lower prevalence of dyslipidemia. Compared with patients with MI-CAD, patients with MINOCA in all age groups (<59, 60-69, 70-79, >80 years of age) had a higher incidence of non-ST-segment-elevation MI. Additionally, those ≤59 years of age were more often women and had a lower prevalence of diabetes and dyslipidemia. In-hospital mortality increased with age in patients with MI-CAD (3.9% for <59 years of age, 5.6% for 60-69 years of age, 8.3% for 70-79 years of age, and 15.2% for >80 years of age; P<0.01), but not in patients with MINOCA (4.5%, 7.4%, 6.0%, and 9.6%, respectively; P=0.36). Compared with patients with MI-CAD, patients with MINOCA had lower in-hospital mortality for Killip class IV (40.7% versus 20.0%; adjusted odds ratio [OR], 0.31 [95% CI, 0.10-0.94]; P=0.04) and renal dysfunction (20.0% versus 7.1%; adjusted OR, 0.29 [95% CI, 0.09-0.96]; P=0.04).

Patients with MINOCA exhibit distinct clinical characteristics and outcomes compared with those with MI-CAD, particularly in terms of age, sex, prevalence of comorbidities, and in-hospital mortality. These findings underscore the importance of tailored clinical approaches for patients with MINOCA.

Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.

This was a secondary analysis of the RENOVATE-COMPLEX-PCI trial (Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) in which patients with complex coronary artery lesions undergoing PCI were enrolled at 20 sites in Korea from May 2018 through May 2021. Patients were randomized to receive intravascular imaging-guided PCI or angiography-guided PCI and classified according to the presence of HBR. The primary end point was target vessel failure, which was a composite of cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization.

Of 1639 trial population, 478 patients met HBR criteria. There was no significant difference in the risk of the primary end point between HBR and non-HBR patients (11.8% versus 8.2%; adjusted hazard ratio [HR], 1.05 [95% CI, 0.72-1.54]; P=0.790). However, patients with HBR were at higher risk for cardiac death or spontaneous target vessel-related myocardial infarction (adjusted HR, 2.04 [95% CI, 1.09-3.80]; P=0.025), all-cause death (adjusted HR, 3.30 [95% CI, 1.93-5.62]; P<0.001), and cardiac death (adjusted HR, 2.36 [95% CI, 1.10-5.09]; P=0.028). Intravascular imaging-guided PCI showed a lower risk of the primary end point compared with angiography-guided PCI in both HBR patients (9.7% versus 15.8%; adjusted HR, 0.57 [95% CI, 0.31-1.02]; P=0.060) and non-HBR patients (6.9% versus 10.8%; adjusted HR, 0.65 [95% CI, 0.43-0.99]; P=0.045), without significant interaction (P for interaction=0.796).

Patients with HBR were associated with an increased risk of adverse cardiovascular events after complex PCI compared with those without HBR. Intravascular imaging-guided PCI showed a lower risk of the target vessel failure without significant interaction between treatment strategy and the presence of HBR in patients undergoing complex PCI.

URL: https://www.clinicaltrials.gov; Unique identifier: NCT03381872.

Myocardial ischemia/reperfusion injury (MIRI) is a significant challenge in the treatment of myocardial infarction, a leading cause of global mortality due to irreversible cardiac damage. Biomimetic nanodelivery systems offer promising therapeutic strategies to address MIRI. In this review, we comprehensively investigate the underlying pathophysiological mechanisms of MIRI and discuss recent advances in biomimetic nanodelivery systems including cell membrane-coated nanoparticles, exosomes, and nanoenzymes as innovative approaches for MIRI treatment. We emphasize the advantages and potential of biomimetic strategies in enhancing therapeutic efficacy, assess the preclinical effectiveness of these nanodelivery systems, and discuss the challenges associated with translating these approaches into clinical practice. This paper aims to provide new perspectives on biomimetic strategies for MIRI treatment, contributing to the development of effective drug delivery systems.

Background: Arterial thrombosis (AT), the main clinical manifestations of which are ischemic heart disease (IHD) and ischemic stroke (IS), is associated with lowered free triiodothyronine (fT3) in acute ischemic stroke (aIS) and acute myocardial infarction (aMI) but increased reverse T3 (rT3) in aMI, which are associated with worse outcomes at one year. Whether such associations remain independent over a longer follow-up period and the value of rT3 in aIS outcomes are largely unknown. This study was dedicated to examining the impact of fT3 and rT3 on aIS and aMI all-cause mortality over a longer 5-year period. Methods: Individuals from Lithuania who experienced aIS and aIM were included in this study. Serum fT3, rT3, free thyroxin and thyroid-stimulating hormone values were examined on admission to the intensive care department. Follow-up for all-cause mortality was divided into two time periods: 1 and 5 years. Results: The final study (aIS cohort age, 67.5 ± 9.6 years, 41.5% women and aMI cohort age, 61.8 ± 11.4 years, 28% women) consisted of 241 aIS and 289 aMI individuals, respectively. Lower fT3 was independently associated (OR = 0.41; 95% CI: 0.17-0.99, p = 0.049) with aIS, and higher rT3 (OR = 1.69; 95% CI: 1.06-2.67, p = 0.027) with aMI with increased all-cause mortality at 1 year. No associations were found between studied hormones and all-cause mortality at 5 years in both conditions. Conclusions: Lower fT3 in aIS and higher rT3 in aMI are associated with higher all-cause mortality at 1 year. No such associations were found at 5 years.

Few studies have investigated the clinical characteristics and in-hospital outcomes of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) using real-world databases in the coronary intervention era.

We conducted a retrospective analysis of 22,236 patients (mean [±SD] age 68±13 years, 23.4% female) enrolled in the Japan Acute Myocardial Infarction Registry (JAMIR) between 2011 and 2016. Based on urgent coronary angiography findings, 286 (1.3%) patients were diagnosed as MINOCA, and the remaining 21,950 (98.7%) as MI with obstructive coronary artery disease (MI-CAD). MINOCA patients were characterized by younger age, fewer coronary risk factors, lower rate of ST-elevation myocardial infarction, lower Killip classification, and lower peak creatinine phosphokinase levels than MI-CAD patients. In-hospital all-cause mortality did not differ between the MINOCA and MI-CAD groups (5.2% vs. 5.7%, respectively; P=0.82). Comparing cause-specific mortality, non-cardiac mortality was higher in the MINOCA than MI-CAD group (4.2% vs. 1.6%; P<0.01). Importantly, non-cardiac death was more prevalent among elderly (≥65 years) than younger (<65 years) patients in the MI-CAD group, whereas this trend was not observed in the MINOCA group.

Analysis of the real-world JAMIR database revealed a relatively high prevalence of non-cardiac death among MINOCA patients, underscoring the need for comprehensive management to improve disease prognosis, particularly in younger patients.

Transatlantic guidelines endorse quality metrics for timely reperfusion in patients with ST-elevation myocardial infarction (STEMI). Compliance in low- and middle-income countries (LMICs) is largely unknown.

We prospectively evaluated 2928 STEMI patients in Kerala, India, across 16 PCI-capable hospitals who received reperfusion with either primary percutaneous coronary intervention (PPCI) or fibrinolysis. Primary endpoint was a major adverse cardiovascular event (MACE) composite of death, non-fatal myocardial infarction, stroke or readmission for heart failure at 1-year.

Among reperfused STEMI patients, 320 (10.9%) received timely reperfusion with either PPCI or fibrinolysis, 1985 (67.8%) received delayed PPCI, and 623 (21.3%) received delayed fibrinolysis. Timely reperfusion had lower unadjusted MACE rates than delayed PCI or fibrinolysis (timely reperfusion: 11.9%, delayed PPCI: 13.6%, delayed fibrinolysis: 23.9%, P < 0.001). Mortality was lowest in the timely reperfusion group (timely reperfusion: 6.3%, delayed PPCI: 7.8%, delayed fibrinolysis 18.8%, P < 0.001). After multivariate analysis, delayed fibrinolysis had a higher MACE rate (HR 1.52 95% CI 1.04-2.21) and mortality (HR 1.97, 95% CI 1.18-3.25) compared to timely reperfusion. Total ischemic time > 3 h and delayed first medical contact-to-needle time predicted MACE at 1 year.

Among STEMI patients in Kerala, India, only one in 10 eligible patients received timely reperfusion. Longer total ischemic times and delayed fibrinolysis were associated with 1-year MACE. Improving timely reperfusion is critical to enhancing STEMI outcomes in LMICs. What is already known on this topic Given the established link between delay to reperfusion and worse major adverse cardiac events (MACE), global efforts have concentrated on minimizing different components of the total ischemic time to improve ST-elevation myocardial infarction (STEMI) outcomes. Compliance in low- and middle-income countries (LMICs) is largely unknown. What this study adds In this cohort of STEMI patients in Kerala, India, total ischemic time and first medical contact-to-needle time correlated with long-term MACE rates, whereas other timeliness indicators did not. How this study might affect research, practice or policy Our study highlights the significant barriers to accessing STEMI care that are prevalent in LMICs despite incremental growth in the number of PCI-capable hospitals. The pre-hospital phase within total ischemic time is the most important quality improvement metric of STEMI care in LMICs, especially for patients chosen for fibrinolysis.

Percutaneous coronary intervention (PCI) is an established alternative to coronary artery bypass grafting for the treatment of select patients with unprotected left main (LM) coronary artery disease (CAD). This study evaluates the safety and clinical impact of treating additional coronary arteries during LM-PCI. Consecutive patients undergoing PCI with drug-eluting stents for unprotected LM-CAD between 2010 and 2021 at The Mount Sinai Hospital, New York, USA were eligible for inclusion. Patients were stratified based on whether they underwent treatment of the LM complex alone or had concomitant PCI to an additional vessel outside the LM complex. The primary outcome was major adverse cardiovascular events (MACE), a composite of death, myocardial infarction, or stroke, at one year following PCI. Among 869 consecutive patients (mean age 70.9, 33.0% female, 27.9 mean SYNTAX score) undergoing LM-PCI, 479 (55.1%) underwent treatment of the LM complex alone, and 390 (44.9%) had concomitant PCI of an additional non-LM vessel. Compared with LM complex PCI only, there were no significant differences in the rate of MACE at one year [HR 12.0% vs. 13.3%; HR: 0.95; 95% CI (0.62 - 1.44), p = 0.797], even after adjustment for potential confounders [HR 12.0% vs. 13.3%; HR: 0.87; 95% CI (0.56 - 1.36), p = 0.550]. In conclusion, in a large, real-world cohort of patients undergoing unprotected LM-PCI, treatment of an additional non-LM vessel did not increase the risk of MACE at 1 year compared to LM complex PCI alone.

ABO blood group's influence on cardiovascular risk, particularly in venous thromboembolism and coronary artery disease (CAD), is well-studied, with non-O blood groups associated with heightened CAD risk. However, its impact on stent thrombosis remains an unexplored area, prompting the question of whether ABO blood groups are also associated with risk of early stent thrombosis.

The primary objective of this study was to analyze the impact of ABO blood groups on the occurrence of early (≤30 days) stent thrombosis.

The study included 10,714 consecutive patients who underwent percutaneous coronary intervention (PCI) with implantation of drug-eluting stents (DES) at a tertiary care hospital. Among these, 78 patients (0.73 %) experienced early stent thrombosis. Propensity score matching was conducted using cardiovascular risk factors and predictors of stent thrombosis, including age, sex, diabetes, hypertension, smoking, hypercholesterinemia, and clinical presentation.

The presence of non-0 blood groups (blood groups A, B and AB; OR 1.48; 95 % CI 0.74-2.97; p = 0.27) and of A-antigen (blood groups A, AB; OR 0.93; 95 % CI 0.51-1.84; p = 0.89) was not associated early stent thrombosis, respectively. In contrast, patients with B-antigen (blood groups B, AB) were at higher risk of early stent thrombosis as compared to patients with blood group 0 (OR 2.48; 95 % CI 1.08-5.69; p = 0.019).

The presence of blood group antigen B (blood groups B and AB) emerged as a significant factor associated with early stent thrombosis. Further investigations are warranted to elucidate the specific biological mechanisms through which ABO blood group antigens could influence stent thrombosis.

In the COMPLETE (Complete vs Culprit-Only Revascularization to Treat Multi-Vessel Disease After Early PCI for STEMI) trial, complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD) reduced important outcomes compared with culprit-only percutaneous coronary intervention. Whether clinical outcomes in STEMI patients with MVD are influenced by the presence of a left anterior descending (LAD) nonculprit lesion (NCL) remains unknown.

This study sought to compare: 1) cardiovascular outcomes among patients with an NCL in the proximal/mid-LAD to patients with an NCL in other locations; and 2) the benefit of NCL revascularization in patients with and without a proximal/mid-LAD NCL.

The COMPLETE trial enrolled patients presenting with STEMI and MVD to angiography-guided complete revascularization vs a culprit lesion-only strategy. All coronary angiograms were evaluated in a central core laboratory. In this prespecified subanalysis, treatment effect according to proximal/mid-NCL location was determined for the coprimary outcomes of: 1) cardiovascular death or new myocardial infarction; and 2) cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. Cox proportional hazards models were performed with an interaction term for treatment allocation and NCL location.

Of the 4,041 subjects in COMPLETE, 1,666 patients had a proximal/mid-LAD NCL (41.2%). The first coprimary outcome occurred in 8.5% (2.9%/y) of patients with a proximal/mid-LAD NCL vs 9.9% (3.4%/y) in those without (adjusted HR: 0.83; 95% CI: 0.67-1.03). Complete revascularization had a similar benefit in reducing the first coprimary outcome for patients with a proximal/mid-LAD NCL (7.7% vs 9.2%; HR: 0.85; 95% CI: 0.61-1.18) and those without (8.0% vs 11.9%; HR: 0.65; 95% CI: 0.50-0.86), with no differential treatment effect (interaction P = 0.235) CONCLUSIONS: Among patients presenting with STEMI and multivessel CAD, those with a proximal/mid-LAD NCL had similar event rates to those without. The benefit of complete revascularization between the groups was similar, with no evidence of heterogeneity.

The changes over time and effects on long-term clinical outcomes beyond 1 year of irregular protrusion (IP) in chronic coronary syndrome (CCS) remains unclear.

This study aimed to assess the time-dependent change and long-term clinical impact of IP in CCS lesions.

This study was a post hoc analysis of COLLABORATION study, which was a multicenter, prospective, observational study conducted from July 2018 to February 2020, assessing 1- and 12-month serial vessel responses after stent implantation using OCT and coronary angioscopy. Time-dependent change in the presence of IP was evaluated using the serial OCT examinations. The cumulative 3-year incidence of TLR was compared between the lesions with and without IP, as well as between those with and without residual IP at 1 month.

Among 107 lesions, IP was detected in post-OCT pullbacks in 38 (35.5%) lesions. Out of the 38 lesions, IP remained in 9 (23.7%) lesions at 1 month and existed in 2 (5.3%) lesions at 12 months. The cumulative 3-year incidence of TLR was significantly higher in IP group than in non-IP group (13.6% vs. 3.0%, p = 0.04). Similarly, it was significantly higher in lesions with residual IP at 1 month than those without (33.3% vs. 4.3%, p < 0.01). All residual IP at 1 month were composed of angioscopic yellow plaques and red thrombi.

The presence of IP decreased over time, but approximately one-fourth of IP remained at 1 month. IP and residual IP at 1 month were important post-stent OCT findings leading to long-term TLR in patients with CCS.

Our objective was to compare the efficacy and safety of a drug-eluting stent featuring an abluminal bioabsorbable sirolimus-containing polymer coating (BP-SES) with an everolimus-eluting stent with a durable polymer (DP-EES) in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs).

TARGET CTO is a multicenter, open-label, noninferiority trial that randomized patients to either BP-SES or DP-EES in a 1:1 fashion following successful CTO re-canalization. The primary endpoint that was powered for noninferiority assessment is in-stent late lumen loss (LLL) at 12 months.

A total of 206 subjects underwent randomization, with 103 assigned to the BP-SES group and 103 to the DP-EES group. Baseline clinical and angiographic characteristics were comparable. The primary endpoint demonstrated noninferiority for the BP-SES group compared to the DP-EES group (0.21 ± 0.43 mm vs 0.21 ± 0.33 mm; P = .934, 2-sided; difference 0.01mm [BP-SES minus DP-EES]; 95% CI: -0.13 to 0.12 mm; p noninferiority < .001,1-sided). No significant differences were observed in secondary angiographic or clinical endpoints. The rates of 12-month in-stent and in-segment binary restenosis in the BP-SES group and the DP-EES group were similar (6.8% vs 7.5%, P = .86; and 8.1% vs 8.8%; P = .89, respectively). Although there was a trend favoring the BP-SES group, the difference between the BP-SES group and DP-EES group at 12 months in target lesion failure (2.1% vs 8.0%, P = .054) and target lesion revascularization (2.1% vs 7.1%, P = .089) did not reach statistical significance. No definite or probable stent thromboses were reported in either group.

Compared to DP-EES, PCI of CTOs with BP-SES showed similar results in terms of late loss and binary restenosis at the 12-month follow-up.

ClinictalTrial.gov, number NCT03040934.

Biomarkers are used for long-term risk prediction of cardiovascular (CV) events in patients presenting with suspected acute coronary syndromes.

This study investigated whether there are sex differences in the long-term prognostic value of biomarkers in patients presenting with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS).

High-sensitivity cardiac troponin T (hs-cTnT), hs-cTnI, N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, and C-reactive protein (CRP) concentrations were measured in 1,476 patients admitted with suspected NSTE-ACS. Patients were followed up for a median of 1,547 (IQR: 873-1,842) days until a primary composite endpoint of all-cause mortality, incident myocardial infarction, or heart failure hospitalization. A secondary endpoint of CV death was also registered.

For the primary endpoint, a log2 increase of hs-cTnT and hs-cTnI concentration was associated with a higher adjusted HR in women (hs-cTnT: 1.3, 95% CI: 1.2-1.5; hs-cTnI: 1.2, 95% CI: 1.1-1.2) than in men (hs-cTnT: 1.1, 95% CI: 1.0-1.2; hs-cTnI: 1.0, 95% CI: 1.0-1.1); P for interaction with sex = 0.009 (hs-cTnT) and 0.005 (hs-cTnI). A similar interaction was shown for NT-proBNP (P for interaction = 0.043). GDF-15 and CRP were independent predictors of the primary endpoint, but the interaction by sex was nonsignificant.

In contrast to CRP and GDF-15, increasing concentrations of hs-cTnT, hs-cTnI, and NT-proBNP are associated with higher risk of death and CV events in female than in male patients presenting with suspected NSTE-ACS. Sex-adjustment of hs-cTn and NT-proBNP may increase the accuracy of long-term CV prognostication in women and men.

Intravascular imaging-guided percutaneous coronary intervention (PCI) has been shown to improve clinical outcomes in patients with complex coronary artery lesions compared with angiography-guided PCI. However, the prognostic impact of suboptimal findings on intravascular imaging such as stent underexpansion, malapposition, or dissection is unclear in the era of contemporary drug-eluting stents.

From RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) which compared imaging-guided PCI with angiography-guided PCI in patients with complex lesions, post-PCI intravascular imaging findings, including minimum stent area (MSA), relative stent underexpansion (MSA≤80% of the average reference lumen area), malapposition, or dissection, were assessed in nonleft main target lesions. The primary end point was target lesion failure (TLF), a composite of cardiac death, target lesion-related myocardial infarction, target lesion revascularization, or definite stent thrombosis.

A total of 897 nonleft main lesions from 714 patients undergoing imaging-guided PCI were included. During a median follow-up duration of 2.1 years, the optimal cutoff value of MSA to predict the occurrence of TLF was 5.5 mm2, and MSA<5.5 mm2 was associated with a significantly higher risk of TLF than MSA≥5.5 mm2 (2.2% versus 4.8%; adjusted hazard ratio, 3.09 [95% CI, 1.01-9.50]; P=0.048). Compared with the reference group (MSA≥5.5 mm2 and no suboptimal findings), the subgroup of patients with MSA≥5.5 mm2 and post-PCI intravascular imaging findings of relative stent underexpansion, major malapposition, or major dissection was associated with a numerically increased risk of TLF (0.0% versus 3.2%; P=0.057). Compared with the same reference group, the subgroup of patients with MSA<5.5 mm2 and suboptimal post-PCI intravascular imaging findings was associated with a significantly increased risk of TLF (0.0% versus 4.7%; P=0.017).

After intravascular imaging-guided PCI with contemporary drug-eluting stents for nonleft main complex lesions, inadequate absolute stent expansion was independently associated with a higher risk of TLF. Suboptimal post-PCI intravascular imaging findings of relative stent underexpansion, major malapposition, and major dissection seem to contribute to the risk of TLF.

https://www.clinicaltrials.gov; Unique identifier: NCT03381872.

The electrocardiogram (ECG) is a ubiquitous medical diagnostic tool employed to localize myocardial infarction (MI) that is characterized by abnormal waveform patterns on the ECG. MI is a serious cardiovascular disease, and accurate, timely diagnosis is crucial for preventing severe outcomes. Current ECG analysis methods mainly rely on intra- and inter-lead feature extraction, but most models overlook the medical knowledge relevant to disease diagnosis. Moreover, existing models often fail to effectively utilize the global spatial relationships within multi-lead ECGs, limiting their ability to comprehensively understand and accurately localize the complex pathological mechanisms of MI. To address these issues, we propose a knowledge-driven overlapping lead grouping method. Based on clinical diagnostic knowledge, we group the 12 leads according to their relevance to MI localization while retaining the full set of 12 leads as a unified group. Additionally, we design a multi-stage learning network that first extracts basic features through initial convolutional layer and progressive convolutional block, followed by SE-enhanced multi-scale residual block and positional Transformer block to gradually learn deeper intra- and inter-lead features. Furthermore, we propose a branch-level weighted feature integration mechanism to effectively fuse the features extracted from each group. The proposed method was thoroughly evaluated on the publicly available multi-label PTB-XL dataset and achieved over 80% prediction accuracy for MI localization tasks. The results demonstrated significant improvements across several metrics compared to current state-of-the-art methods, confirming its exceptional performance.

Preclinical studies demonstrate a cardioprotective role of eosinophils in acute myocardial infarction. Yet clinical studies show conflicting correlations between blood eosinophil counts and acute myocardial infarction risk and mortality. This study evaluates blood eosinophil counts of patients with acute myocardial infarction at hospital admission (EOSbaseline) and discharge (EOSpost) on all-cause and cardiac mortalities.

Of 2681 consecutive patients with a median follow-up of 2.55 years, 45 patients died within 30 days, 28 died within 30 to 150 days, and 92 died within 150 days or later postdischarge. Cardiac death occurred in 108 patients. According to the receiver operating characteristic analyses, the best cutoffs of EOSbaseline and EOSpost were 0.02×109/L and 0.03×109/L, respectively, to predict 30-day all-cause death (area under the curve [AUC]baseline, 0.60; AUCpost, 0.67). The optimal cutoffs of EOSbaseline and EOSpost were 0.20×109/L and 0.14×109/L to predict long-term all-cause mortality (1-year AUCbaseline, 0.59; 1-year AUCpost, 0.61). Multivariate logistic analysis showed that low EOSbaseline (<0.02×109/L) or low EOSpost (<0.03×109/L) predicted the 30-day all-cause (odds ratio [OR]baseline, 2.56; P=0.005; ORpost, 8.14; P<0.001) and cardiac (ORbaseline, 2.16; P=0.025; ORpost, 7.89; P<0.001) mortalities. Patients with combined low EOSbaseline (<0.02×109/L) and low EOSpost (<0.03×109/L) displayed synergistic risk of 30-day all-cause (OR, 13.93; P<0.001) and cardiac (OR, 11.38; P<0.001) deaths. In contrast, adjusted Cox proportional hazard test indicated that high EOSpost (≥0.14×109/L) was an independent risk for long-term all-cause mortality (hazard ratio, 1.84; P=0.010).

High and low blood eosinophil counts both predict the risk of all-cause and cardiac deaths in patients with acute myocardial infarction depending on the time of data collection. Dynamic changes of blood eosinophil counts offer a more accurate prediction of post-myocardial infarction deaths than a single time point data analysis.

Extracorporeal cardiopulmonary resuscitation (ECPR) has allowed patients with refractory out-of-hospital cardiac arrest (OHCA) due to acute myocardial infarction (AMI) to receive primary percutaneous coronary intervention (PCI); they were previously ineligible.

The purpose of this study was to clarify the characteristics and outcomes of patients with OHCA secondary to AMI who underwent primary PCI during refractory cardiac arrest despite ECPR.

Patients with AMI and OHCA aged ≥18 years who underwent PCI with ECPR in 2013 to 2018 were identified from a multicenter ECPR registry in Japan. The primary outcome was in-hospital mortality. We also assessed possible predictors of survival to discharge using mixed effects logistic regression to account for group differences among facilities.

Among 671 patients with AMI and OHCA who underwent PCI with ECPR from 30 institutions, 251 (37%) patients had refractory cardiac arrest despite ECPR initiation and subsequently underwent primary PCI. Following coronary reperfusion, 64.9% (163/251) of patients achieved the sustained return of spontaneous circulation (ROSC), 21.1% (53/251) survived, and 10.4% (26/251) had favorable neurological status at hospital discharge. Multivariable analysis revealed that intermittent prehospital ROSC (OR: 5.22; 95% CI: 1.54-17.79), shorter time to ECPR initiation (OR: 0.89; 95% CI: 0.82-0.98), and postprocedural TIMI flow grade 3 (OR: 5.08; 95% CI: 1.50-17.22) are significantly associated with survival to hospital discharge.

Among patients with AMI and refractory OHCA treated with ECPR, one-third did not have sustained ROSC prior to PCI. Of those, two-thirds achieved sustained ROSC following reperfusion and one-fifth survived to discharge.

Data on percutaneous coronary intervention (PCI) for left main coronary artery (LMCA) disease in patients of diverse race/ethnicity are scant. This study aimed to assess the impact of race/ethnicity on clinical outcomes at 12-month follow-up of patients with LMCA disease who underwent PCI with drug-eluting stent implantation. All patients who underwent PCI for LMCA disease between 2010 and 2019 at a tertiary care center were prospectively enrolled. Clinical outcomes were assessed per each race/ethnic group. The primary end point was the composite of all-cause death, myocardial infarction, or stroke at 12 months. A total of 774 consecutive patients with known race/ethnicity were prospectively enrolled (62.1% [n = 481] Caucasian, 17.2% [n = 133] Hispanic, 12.7% [n = 98] Asian, and 8.0% [n = 62] African-American). Compared with Caucasians, the hazard rate of the primary end point tended to be lower in Asian patients (6.1% vs 14.2%; hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.16 to 1.03) and similar in African-American (13.7% vs 14.2%; HR 0.93, 95% CI 0.40 to 2.16) and Hispanic patients (14.2% vs 14.2%; HR 1.02, 95% CI 0.58 to 1.78). Hazard rates of target vessel or lesion revascularization were comparable among the 4 groups. Cox multivariable regression adjustment confirmed consistent findings and revealed higher hazard rates of postdischarge bleeding in African-Americans compared with Caucasians (HR 5.89, 95% CI 1.00 to 34.5). In conclusion, within a racially/ethnically diverse cohort of patients who underwent PCI for LMCA disease, when compared with Caucasians, Asians had lower risk of all-cause death, myocardial infarction, or stroke, whereas African-Americans had increased risk of postdischarge bleeding.

The study 'Periodontitis and Its Relation to Coronary Artery Disease' (PAROKRANK) reported an association between periodontitis (PD) and the first myocardial infarction (MI). This follow-up study aims to test the hypothesis that those with PD-compared to periodontally healthy individuals-are at increased risk for cardiovascular (CV) events and death.

A total of 1587 participants (age <75 years; females 19%) had a dental examination including panoramic radiographs between 2010 and 2014. PD was categorized as healthy (≥80% alveolar bone height), mild/moderate (79%-66%) or severe (<66%). A composite CV event (first of all-cause death, non-fatal MI or stroke and hospitalization following to heart failure) was investigated during a mean follow-up period of 9.9 years (range 0.2-12.5 years). Participants were divided into two groups: those with and without PD. The primary event rate, stratified by periodontal status at baseline, was calculated using the Kaplan-Meier method and Cox regression.

The number of events was 187 in the 985 periodontally healthy participants (19%) and 174 in the 602 participants with PD (29%; p < 0.0001). Those with PD had a higher likelihood for a future event (hazard ratio [HR] = 1.26; 95% CI: 1.01-1.57; p = 0.038), following adjustment for age, smoking and diabetes.

The PAROKRANK follow-up revealed that CV events were more common among participants with PD, which supports the assumption that there might be a direct relation between PD and CV disease.

Owing to the time-sensitive nature of myocardial ischemia, challenging clinical scenarios should be considered in patients with type A acute aortic dissection (AAAD) complicated by coronary malperfusion. In clinical settings, the diagnosis and reperfusion strategies for coronary malperfusion often depend on institutional resources. This study evaluated early surgical outcomes in such patients, focusing on transportation type and clinical management.

We retrospectively reviewed 70 patients who underwent emergency surgery for AAAD with coronary malperfusion, excluding those with cardiac tamponade on arrival, between 1997 and February 2024. Patients were divided into 2 groups based on transportation: direct transfer and referral.

Overall, in-hospital mortality was 27%, with only 1 of 9 patients surviving with preoperative peripheral extracorporeal membrane oxygenation (ECMO). Mortality and morbidity did not significantly differ between groups. Univariate analysis identified left coronary artery involvement and preoperative hemodynamic instability as significant risk factors. Additionally, preoperative diagnostic-only coronary angiography (CAG) with unsuccessful reperfusion was a potential risk factor (P = 0.06).

Regardless of transportation type, preoperative peripheral ECMO itself could not be a definitive solution in AAAD patients with coronary malperfusion. Also, patients who underwent preoperative CAG with unsuccessful reperfusion might be fatal, especially with suspected left coronary artery involvement.